Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects

British Journal of Clinical Pharmacology
W DieterleJ Mann

Abstract

To investigate the effects of aliskiren, an oral renin inhibitor, on the pharmacokinetics and pharmacodynamics of warfarin. In a single-blind, placebo-controlled, randomized, two-period crossover study, 15 healthy male and female subjects received a single oral dose of 25 mg racemic warfarin twice, once in the morning of the 8th day of treatment with 150 mg aliskiren and once at the same time point during treatment with placebo. Blood samples were collected for the measurement of prothrombin time (PT) and activated thromboplastin time (aPTT) and for determination of plasma concentrations of (R)- and (S)-warfarin. Aliskiren treatment had no effect on the blood coagulation parameters (PT, INR and aPTT). The ratios of least square means (90% CI) of pharmacokinetic parameters in the presence and absence of aliskiren for (R)- and (S)-warfarin were Cmax 0.89 (0.82, 0.96) and 0.88 (0.80, 0.97), AUC(0, infinity) 1.00 (0.94, 1.07) and 1.06 (0.96, 1.16) and t(1/2) 0.99 (0.92, 1.07) and 1.05 (0.96, 1.14). Multiple doses of aliskiren had no detectable effect on the pharmacokinetics or pharmacodynamics of a single dose of warfarin in healthy subjects.

References

Jun 1, 1996·Clinical Pharmacokinetics·S Harder, P Thürmann
Jan 1, 1997·Pharmacology & Therapeutics·L S Kaminsky, Z Y Zhang
Feb 28, 2001·Expert Opinion on Investigational Drugs·N D Fisher, N K Hollenberg
Aug 21, 2003·Biochemical and Biophysical Research Communications·Jeanette M WoodMartin P Bedigian

❮ Previous
Next ❯

Citations

Mar 28, 2008·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Michel Azizi
Jan 25, 2012·Journal of Pharmacokinetics and Pharmacodynamics·Kerenaftali KleinLeon Aarons
Mar 20, 2009·International Urology and Nephrology·Yasmin PashaDavid Goldsmith
Aug 10, 2007·Current Hypertension Reports·Helmy M Siragy
Aug 18, 2006·Current Opinion in Nephrology and Hypertension·Michel Azizi
Aug 19, 2007·Cardiology in Review·Reza SepehrdadDomenic A Sica
Dec 20, 2007·Cardiology in Review·Sum Lam, Mary Choy
May 19, 2010·American Journal of Therapeutics·Zafar H IsrailiValmore Bermúdez
Mar 1, 2008·Clinical and Experimental Pharmacology & Physiology·Grégoire Wuerzner, Michel Azizi
Feb 16, 2008·The Journal of Clinical Investigation·Hong LuAlan Daugherty
Jul 10, 2008·Clinical Pharmacokinetics·Sujata VaidyanathanWilliam P Dole
Nov 26, 2010·Expert Opinion on Drug Metabolism & Toxicology·Gianpaolo ReboldiPaolo Verdecchia
Jun 26, 2012·Expert Opinion on Drug Safety·Fabio AngeliPaolo Verdecchia
Aug 9, 2008·Current Medical Research and Opinion·Haroonur Rashid
Mar 18, 2008·Clinical Therapeutics·Judy W M Cheng
Jan 25, 2007·Journal of Clinical Pharmacology·Sujata VaidyanathanWilliam P Dole
Mar 17, 2012·The Journal of Pharmacy and Pharmacology·Azhar RashikhAbul Kalam Najmi
Feb 2, 2008·Journal of the American College of Cardiology·Alan H Gradman, Rishi Kad
Oct 24, 2006·Lancet·Jan A StaessenTom Richart
Aug 19, 2007·Journal of Cardiovascular Pharmacology·A H Jan Danser
Apr 24, 2009·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Eva VetsAnthony Shane Jackson
Jul 3, 2008·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Kimberly K Daugherty
Mar 11, 2008·Expert Review of Cardiovascular Therapy·Steven G Chrysant
Feb 15, 2011·American Journal of Therapeutics·Addison A Taylor, James L Pool
Aug 9, 2007·Drugs·James E Frampton, Monique P Curran
May 19, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Felix WaldmeierSujata Vaidyanathan
Mar 8, 2007·The Annals of Pharmacotherapy·Benjamin W Van Tassell, Mark A Munger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.